This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Rigel Pharmaceuticals, Inc.
Drug Names(s): PF-03526299, R-343, R940343
Description: R343 is a small molecule syk kinase inhibitor. Syk kinase regulates IgE receptor signaling in mast cells and thus interfering with its activity may prevent cellular activation and subsequent release of multiple chemical mediators. R343 is not orally bioavailable, but will be delivered by a dry powder inhaler.
Deal Structure: In January 2005, Rigel Pharmaceuticals and Pfizer entered into a collaborative research and license agreement for the development of inhaled products for the treatment of allergic asthma and other respiratory diseases such as chronic obstructive pulmonary disease (COPD). The collaboration is focused on Rigel's preclinical small molecule compounds, which inhibit IgE receptor signaling in respiratory tract mast cells by blocking the signaling enzyme Syk kinase. Under the terms of the agreement, Rigel will receive an upfront cashpayment, as well as milestone payments and royalties on any future product sales. Pfizer will make an equity investment in Rigel and will be responsible for the worldwide development and commercialization of any resulting products.Financial terms of the agreement were not announced.
In May 2011, Rigel assumed development of R343 after Pfizer returned full rights to the program as a result of Pfizer exiting the allergy and respiratory therapeutic area within R&D.
Additional information available to subscribers only: